Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors

@inproceedings{Molife2014Phase1T,
  title={Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors},
  author={Lulama Rhoda Molife and Li Yan and Joanna Vitfell-Rasmussen and Adriane M Zernhelt and Daniel Sullivan and Philippe Alexandre Cassier and Eric Xueyu Chen and Andrea Biondo and Ernestina Tetteh and Lillian L. Siu and Amita Patnaik and Kyriakos P. Papadopoulos and Johann S de Bono and Anthony William Tolcher and Susan E. Minton},
  booktitle={Journal of hematology & oncology},
  year={2014}
}
BACKGROUND Inhibition of AKT with MK-2206 has demonstrated synergism with anticancer agents. This phase 1 study assessed the MTD, DLTs, PK, and efficacy of MK-2206 in combination with cytotoxic and targeted therapies. METHODS Advanced solid tumor patients received oral MK-2206 45 or 60 mg (QOD) with either carboplatin (AUC 6.0) and paclitaxel 200 mg/m2… CONTINUE READING
  • Blog articles referencing this paper

  • Presentations referencing similar topics